 IRVINE, CA ACCESSWIRE April 28, 2020 Hancock Jaffe Laboratories, Inc. HJLIHJLIW, a developer of medical devices that restore cardiac and vascular health, announced today that five VenoValve patients from HJLIs first-in-man, clinical study in Colombia have now reached the one-year milestone following VenoValve surgery, and that chronic venous insufficiency CVI has significantly improved in all five patients when compared to pre-surgery levels. On average, the five patients showed an 8.2 point improvement in VCSS scores at one year, compared to pre-surgery levels. The improvements in VCSS scores is significant and indicates that VenoValve patients who had severe CVI pre-surgery, now have mild CVI or the complete absence of disease at one-year post surgery. 